SCHEMBL296297

SCHEMBL296297

CCCCCCS([O])(=O)=O

nearest known ligand 0.59

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.59
CA2 P00918 6/20 0.52
TSHR P16473 1/20 0.47
THRB P10828 1/20 0.47
CES1 P23141 5/20 0.42
CES2 O00748 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL547132 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL77261 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL304723 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL546219 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL4880167 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL303807 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL77270 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL4880544 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL301132 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL303667 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 908 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103464049-A Perfluorohexyl sulfonyloxy benzyl cation surfactant as well as preparation method and application thereof UNIV HUAZHONG NORMAL 2013-12-25 CN claimed
CN-103432708-A Perfluoro-hexyl sulphonyl oxygen benzyl amine oxide surface active agent as well asand preparation method and application thereof UNIV HUAZHONG NORMAL 2013-12-11 CN claimed
US-8492390-B2 Synthesis of locked nucleic acid derivatives SANTARIS PHARMA A/S (DK) 2013-07-23 US claimed
US-8084458-B2 Synthesis of locked nucleic acid derivatives SANTARIS PHARMA A/S (DK) 2011-12-27 US claimed
US-20100216983-A1 SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES SANTARIS PHARMA A/S, a Denmark corporation 2010-08-26 US claimed
US-7619095-B2 Process for the preparation of indolone derivative ALEMBIC LIMITED (IN) 2009-11-17 US claimed
EP-1848691-B1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE ALEMBIC LTD (IN) 2009-11-11 EP claimed
US-7569575-B2 Formed via intermediates which are reactive with nucleophiles SANTARIS PHARMA A/S (DK) 2009-08-04 US claimed
EP-1845088-B1 An improved process for the preparation of aripipirazole RANBAXY LAB LTD (IN) 2009-07-22 EP claimed
US-20080262244-A1 Process for the Preparation of Indolone Derivative ALEMBIC LIMITED (IN) 2008-10-23 US claimed
EP-1848691-A1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE Alembic Limited (IN) 2007-10-31 EP claimed
EP-1845088-A1 An improved process for the preparation of aripipirazole Ranbaxy Laboratories Limited (IN) 2007-10-17 EP claimed
US-20070238876-A1 PROCESS FOR THE PREPARATION OF ARIPIPRAZOLE RANBAXY LABORATORIES LIMITED (IN) 2007-10-11 US claimed
EP-1501848-B1 SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES SANTARIS PHARMA AS (DK) 2007-08-08 EP claimed
WO-2006123356-A1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE ALEMBIC LIMITED (IN) 2006-11-23 WO claimed
EP-1163250-B1 IMPROVED SYNTHESIS OF ¬2.2.1|BICYCLO NUCLEOSIDES EXIQON AS (DK) 2006-07-12 EP claimed
EP-1501848-A1 SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES Santaris Pharma A/S (DK) 2005-02-02 EP claimed
US-20040014959-A1 Synthesis of locked nucleic acid derivatives SANTARIS PHARMA A/S (DK) 2004-01-22 US claimed
WO-2003095467-A1 SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES SANTARIS PHARMA A/S (DK) 2003-11-20 WO claimed
US-4140684-A FOR POLYESTERS, POLYAMIDES, AND CELLULOSE ACETATES FIDELITY UNION TRUST COMPANY, EXECUTIVE TRUSTEE UNDER THE SANDOZ TRUST (US) 1979-02-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238876-A1 PROCESS FOR THE PREPARATION OF ARIPIPRAZOLE CYP2F1, CYP2C19, CYP2A6 FAAH 1213/4885CA2 21/4885TSHR 2690/4885
US-20100216983-A1 SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES RNGTT, NSUN3, NSUN2 FAAH 2365/4885CA2 3961/4885TSHR 1240/4885
US-20040014959-A1 Synthesis of locked nucleic acid derivatives NSUN3, RNGTT, NSUN2 FAAH 2292/4885CA2 3938/4885TSHR 1165/4885
US-20080262244-A1 Process for the Preparation of Indolone Derivative HTR3C, HTR3B, HTR1B FAAH 2513/4885CA2 3810/4885TSHR 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.